MetMAb Looking Very Promising for (About Half of) Patients with Advanced NSCLC Article We've already discussed prior work on Met as a potentially valuable target in NSCLC, as illustrated by work with ARQ-197 combined with the EGFR inhibitor Tarceva (erlotinib) has demonstrated encouraging early results. Read more about MetMAb Looking Very Promising for (About Half of) Patients with Advanced NSCLC9 comments
